Trial0

Clinical trial · NCT07796347

Dyadic Life Review Intervention for Older Patients With Advanced Cancer and Alzheimer's Disease and Related Dementias and Their Caregivers

Not yet recruiting

Sponsor: University of Rochester

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The purpose of this study is to evaluate the efficacy of Dyadic Life Review (DLR) therapy for reducing caregiver distress, measured by caregiver burden to capture the multifaceted experience of distress, among older adults with advanced cancer and cognitive impairment and their caregivers.

Interventions

  • Dyadic Life Review · BEHAVIORAL

    DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Age ≥65
* Stage III or IV cancer diagnosis, of any type
* The Montreal Cognitive Assessment (MoCA) in-person or MoCA-telephone version ≥15
* Katz Activities of Daily Living (ADL) ≥5
* Able to read and understand English
* Be able to provide informed consent (as measured by UBACC) or have a Legally Authorized Representative to provide informed consent, which can include the participating caregiver.

Caregiver Inclusion Criteria:

* Age 50 or older
* Caregivers are defined is a "significant other, spouse, romantic partner, or adult child with whom you discuss or who can be helpful in health-related matters;"
* Modified Caregiver Strain Index ≥ 5
* Able to read and understand English

Patient Exclusion Criteria:

* No caregiver willing to participate in the study

Caregiver Exclusion Criteria:

• Caregivers unable to provide consent

Sites (1)

  • University of Rochester, Rochester, New York

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-09-01.